Open AccessCirculating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers
Author(s) -
Brett S. Walker,
Thomas L. Sutton,
Luai Zarour,
John G. Hunter,
Stephanie G. Wood,
V. Liana Tsikitis,
Daniel O. Herzig,
Charles D. Lopez,
Emerson Y. Chen,
Skye C. Mayo,
Melissa H. Wong
Publication year - 2021
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-021-10379-2
Subject(s) - medicine , biomarker , gastroenterology , response evaluation criteria in solid tumors , oncology , surgical oncology , colorectal cancer , liquid biopsy , adenocarcinoma , peripheral blood mononuclear cell , neoadjuvant therapy , minimal residual disease , disease , progressive disease , cancer , biochemistry , chemistry , leukemia , breast cancer , in vitro
Real-time monitoring of treatment response with a liquid biomarker has potential to inform treatment decisions for patients with rectal adenocarcinoma (RAC), esophageal adenocarcinoma (EAC), and colorectal liver metastasis (CRLM). Circulating hybrid cells (CHCs), which have both immune and tumor cell phenotypes, are detectable in the peripheral blood of patients with gastrointestinal cancers, but their potential as an indicator of treatment response is unexplored.